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Due to their fundamental role in energy production, mitochondria have been traditionally known as the
powerhouse of the cell. Recent discoveries have suggested crucial roles of mitochondria in the maintenance
of pluripotency, differentiation, and reprogramming of induced pluripotent stem cells (iPSCs). While glyco-
lytic energy production is observed at pluripotent states, an increase in mitochondrial oxidative phosphory-
lation is necessary for cell differentiation. Consequently, a transition from somatic mitochondrial oxidative
metabolism to glycolysis seems to be required for successful reprogramming. Future research aiming to
dissect the roles of mitochondria in the establishment and homeostasis of pluripotency, as well as combining
cell reprogramming with gene editing technologies, may unearth novel insights into our understanding of
mitochondrial diseases and aging.Mitochondria are highly specialized and dynamic double-mem-
brane organelles of bacterial origin that play fundamental roles
in multiple processes in eukaryotic cells, including energy pro-
duction, calcium homeostasis, cell signaling, and apoptosis
(Dyall et al., 2004). In order to meet different demands of distinct
cell types and tissues, cells modulate mitochondrial function
through biogenesis and degradation as well as dynamic fusion
and fission events. Mitochondria are semiautonomous organ-
elles and contain their own genome of 16.6 kb circular mito-
chondrial DNA (mtDNA), encoding for 13 essential protein
subunits of complexes I, III, IV, and V of the respiratory chain
as well as 22 tRNAs and 2 rRNAs necessary for the translation
of mitochondrial subunits (Anderson et al., 1981). Mitochondrial
biogenesis is accomplished by the coordinated expression of
genes from the nuclear and mitochondrial genome. Transcrip-
tional regulators of mitochondrial biogenesis include the nuclear
transcription factors (NRF-1, NRF-2, and ERR1) and transcrip-
tion cofactors (PGC1-a, PGC1-b, and PPRC) as well as nu-
clear-encoded assembly factors necessary for the correct as-
sembly of the respiratory complexes. The nuclear-encoded
DNA polymerase (POLG and POLG2) and mitochondrial tran-
scription factor A (TFAM) are key regulators of mtDNA replica-
tion. In addition, mitochondria are highly dynamic organelles
that undergo cycles of fusion and fission important for their func-
tion, maintenance, and quality control (Chen and Chan, 2009;
Westermann, 2010). On the other hand, mitochondria are the
major sources of endogenous reactive oxygen species (ROS),
which are by-products of ATP production through oxidative
phosphorylation (OXPHOS). Although high levels of ROS may
cause protein carbonylation, lipid peroxidation, and DNA dam-
age and have deleterious effects for the cells, recent studies
have also suggested a physiological role for low levels of ROS
(Sena and Chandel, 2012). Besides their key role in energy pro-
duction through oxidative phosphorylation, mitochondria are
also the sites of essential pathways of intermediate metabolism,amino acid biosynthesis, fatty acid oxidation, and steroid meta-
bolism. In addition to these biochemical functions, mitochondria
also possess important functions in many other essential pro-
cesses including the maintenance of calcium homeostasis (Ja-
cobson and Duchen, 2004), redox regulation (Dro¨ge, 2002),
and apoptosis (Danial and Korsmeyer, 2004). Recently, mito-
chondria have been closely linked to cell fate determination
and development, and several reports have demonstrated
important roles for mitochondria in stem cells (Folmes et al.,
2012; Rafalski et al., 2012). In this review, we summarize recent
discoveries from mitochondrial studies in stem cells, formulate
open questions, and prospect future impacts of the novel find-
ings in the clinic.
Mitochondria and Pluripotency
Pluripotent stem cells (PSCs) represent a remarkable cell type
because of their ability to self-renew and differentiate into any
tissue of the three germ layers, which confers on them great
potential for diseasemodeling, drug screening, and cell-replace-
ment therapies. Recent studies have demonstrated that there is
a strong connection between mitochondrial function and plurip-
otency (Ahlqvist et al., 2012; Folmes et al., 2011; Lapasset et al.,
2011; Prigione et al., 2010; Zhang et al., 2011; Zhou et al., 2012).
Under self-renewing conditions characterized by high expres-
sion of pluripotent genes (Nanog, Oct4, and Sox2), cellular
metabolism has been suggested to play an essential role in the
regulation of pluripotency (Mandal et al., 2011). Compared to
adult somatic cells that utilize an aerobic metabolism based on
oxidative phosphorylation for energy production, PSCs rely
heavily on anaerobic glycolysis (Folmes et al., 2011; Kondoh
et al., 2007; Prigione et al., 2010). Glycolysis provides important
cofactors and substrates to meet the biosynthetic demands and
support cell proliferation of PSCs. More importantly, although
glycolysis is less efficient in terms of energy production, it
produces energy at a faster rate with lower ROS generation,Cell Metabolism 18, September 3, 2013 ª2013 Elsevier Inc. 325
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conditions. Along this line, while stimulation of glycolysis by
hypoxia or inhibition of mitochondrial respiration promotes
pluripotency (Ezashi et al., 2005; Varum et al., 2009), inhibition
of glycolysis or enhancement of mitochondrial function, by either
chemical treatment or overexpression of transcriptional factors,
impairs stemness and differentiation efficiency of PSCs (Kondoh
et al., 2007; Prowse et al., 2012). While mitochondria in adult
somatic cells possess a complex morphology with a well-
developed cristae, denser matrix, and elongated or branched
appearance, consistent with their metabolic state, PSCs contain
functionally immaturemitochondria with a globular shape, poorly
developed cristae, and perinuclear localization, all indicative of a
less active mitochondrial state (Chung et al., 2010; Facucho-
Oliveira and St John, 2009; Prigione et al., 2010; St John et al.,
2005; Suhr et al., 2010). It has been suggested that the
morphology, localization, abundance, and function of mitochon-
dria could be used as markers of pluripotency (Lonergan et al.,
2007). Indeed, mitochondrial staining has been used as a stem
cell indicator in the enrichment of somatic stem cells, such as
hematopoietic stem cells (Romero-Moya et al., 2013). Interest-
ingly, although the energy production of PSCs favors glycolysis
over OXPHOS, mitochondria in PSCs still possess functional
respiratory complexes. While regulation of the preference for
energy production in metabolism is still unclear, several clues
have been suggested, including the decoupling of glycolysis
from OXPHOS by shunting pyruvate out of the mitochondria by
mitochondrial uncoupling protein 2 (UCP2) (Zhang et al., 2011),
along with higher levels of the glycolytic enzyme Hexokinase II
and lower levels of Pyruvate Dehydrogenase (PDH) in PSCs
(Varum et al., 2011).
Mitochondrial homeostasis in the pluripotent state relies on
mitochondrial biogenesis and dynamics (fission and fusion), as
well as degradation through mitochondria autophagy (mitoph-
agy). Although some initial studies have shown that PSCs
contain less mitochondrial content (Prigione et al., 2010; St
John et al., 2006) and lower mtDNA copy number (Facucho-
Oliveira et al., 2007) when compared with somatic cells, recent
publications have clarified that when mitochondrial mass, as
measured by mitochondrial proteins, mitochondrial labeling,
and mtDNA copy number, is normalized to total cellular mass,
the ratio between these cellular parameters is similar in PSCs
and differentiated cells (Birket et al., 2011; Zhang et al., 2011).
The regulation of mtDNA copy number seems to be linked with
the epigenetic methylation of the nuclear-encoded mitochondria
DNA polymerase gamma catalytic subunit (POLG) in a tissue-
specificmanner (Kelly et al., 2012a). Knockdown ofmitochondria
DNA polymerase POLG in mouse embryonic stem cells (ESCs)
results in reduced OCT4 expression and slightly increased levels
of the mesodermal marker Brachyury (Facucho-Oliveira et al.,
2007). In addition to biogenesis, mitochondrial dynamics is
also actively involved in stem cell biology. Gene knockdown of
the mitochondrial protein Gfer (growth factor erv1-like) in mouse
ESCs leads to decreased levels of pluripotent markers (NANOG,
OCT4, SSEA) through the regulation of dynamin-related protein 1
(Drp1), an important mitochondrial fission GTPase. Inhibition of
Drp1 activity rescues structural and functional mitochondrial
dysfunctions and restores the pluripotent gene expression
caused by Gfer deficiency. Unexpectedly, these data demon-326 Cell Metabolism 18, September 3, 2013 ª2013 Elsevier Inc.strate, for the first time, that despite the glycolytic metabolic
state of PSCs, mitochondrial dynamics and maintenance of
proper mitochondrial network integrity are crucial for themainte-
nance of pluripotency (Todd et al., 2010).
More recently, direct evidence for the effect of mtDNA haplo-
types on ESCswas demonstrated inmouse ESCs. Kelly et al. es-
tablished isogenic mouse ESC lines that were different in their
mtDNA haplotypes and found that expression of some pluripo-
tent genes in those lines was different, whichmay partially reflect
epigenetic alternations of these genes. Moreover, they found
that mtDNA haplotypes influence not only chromosomal gene
expression but also cell fate determination upon differentiation.
Kelly’s study presents evidence that mtDNA may regulate nu-
clear gene expression at the pluripotent state and suggests a po-
tential interesting crosstalk between mtDNA and nuclear DNA in
PSCs (Kelly et al., 2012b). Since a similar communication be-
tween mitochondria and the nucleus known as mitochondria
retrograde pathway has been already described in yeast and
mammalian cells, it would be of great interest to investigate if
this pathway could be involved in the regulation of pluripotency
by mitochondria (Butow and Avadhani, 2004).
Mitochondria and Differentiation
During the establishment of pluripotency, a specific remodeling
of mitochondria and metabolism occurs in order to meet the
energetic and anabolic demands of the pluripotent state. Conse-
quently, differentiation of pluripotent cells requires remodeling of
mitochondrial dynamics and bioenergetic system. Upon cell dif-
ferentiation, higher amounts of energy are necessary to sustain
specialized functions in different tissues while the lower prolifer-
ation capacity and necessity of anabolic precursors allow for a
more efficient conversion of metabolic substrates into ATP
(Folmes et al., 2012). Therefore, mitochondria undergo sig-
nificant changes during cellular differentiation, mtDNA copy
number is elevated, and mitochondrial morphology displays a
structurally mature state with dense matrix, complex cristae,
and dispersed cytoplasmic localization (Facucho-Oliveira et al.,
2007; Lonergan et al., 2007; Prigione et al., 2010; Suhr et al.,
2010).
In addition, several studies have demonstrated that differenti-
ation of PSCs induces a spectrum of mitochondrial functional
changes, including increased mitochondrial mass and function,
upregulation of enzymes of the tricarboxylic acid (TCA) cycle
and subunits of the mitochondrial respiratory chain, increased
oxygen consumption and ROS levels, and reduced reliance on
anaerobic glycolysis-based energy generation with the conse-
quent downregulation of glycolytic enzymes (Armstrong et al.,
2010; Chung et al., 2007; Prigione et al., 2010; Tormos et al.,
2011). Once again, metabolic transition from glycolysis to oxida-
tive phosphorylation is necessary for cellular differentiation.
While inhibition of key glycolytic enzymes promotes differentia-
tion, impairment of mitochondrial function with respiratory inhib-
itors improves pluripotency gene expression and blocks PSC
differentiation (Chung et al., 2007; Mandal et al., 2011). Never-
theless, the disturbance of differentiation caused by the respira-
tory inhibitors used in these studies, such as CCCP (carbonyl
cyanide m-chlorophenylhydrazone), antimycin A, or rotenone,
may have not only been caused by the inhibition of mitochondrial
respiratory chain, but also by the toxic and pleiotropic effects of
Figure 1. Simplified Scheme of
Mitochondrial and Metabolic Differences
between Differentiated Cells and
Pluripotent Stem Cells
(A) Upon differentiation, PSCs undergo mitochon-
drial maturation and bioenergetic transition from
anaerobic to aerobic metabolism. Mitochondrial
biogenesis increases mitochondrial number, res-
piratory chain complex density, and ATP produc-
tion. Morphologically, mitochondria become elon-
gated and cristae-rich. Additionally, the TCA cycle
is activated as result of low levels of UCP2 (blue).
(B) Upon reprogramming, differentiated cells
exhibit mitochondrial resetting to a functionally
immature state and a transition from aerobic
to anaerobic metabolism. The mitochondrial
morphology is altered, and mitochondrial content
is reduced. As the consequence of an increase
in glycolysis and decrease in oxidative phos-
phorylation, ATP level decreases, and lactate
production increases. Meanwhile, TCA cycle is
suppressed due to high levels of UCP2 (red).
Abbreviations: PSCs, pluripotent stem cells;
mtDNA, mitochondrial DNA; TCA, tricarboxylic
acid cycle.
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how respiratory inhibitors block PSC differentiation may need
further investigation. The main differences of mitochondrial
function and structure between PSCs and differentiated cells
are summarized in Figure 1. Despite the changes observed in
mitochondrial function and metabolism between PSCs and
differentiated cells, mechanisms responsible for the switch of
bioenergetic metabolism from glycolysis to the more efficient
oxidative phosphorylation remain unclear. Nevertheless, a
recent study by Zhang et al. (2011) showed that mitochondria
of PSCs are capable of consuming oxygen at rates similar to
differentiated cells. Moreover, UCP2, amember of themitochon-
drial uncoupling protein (UCP) family, plays crucial roles in
coupling glycolysis to OXPHOS during PSC differentiation
(Figure 1). In differentiated cells, glycolysis is more coupled to
OXPHOS, whereas the uptake of glucose is less coupled to OX-
PHOS in PSCs. Zhang et al. found that at early stage of differen-
tiation, PSC proliferation slowed down, energy metabolism
decreased, and UCP2 expression was reduced. These changes
accompanied with in a switch from efficient glycolysis to
increased mitochondrial glucose oxidation. Furthermore, UCP2
knockdown decreased the production of lactate, while ectopic
expression of UCP2 suppressed OXPHOS and impeded PSC
differentiation. On the other hand, UCP2 knockdown did not
impair self-renewal of PSCs. Taken together, these findings
demonstrate an important role of UCP2 in PSC differentiation
and show that UCP2-mediated suppression of OXPHOS is
required for the maintenance of pluripotency. In a similar
manner, mitochondrial maturation plays a fundamental role dur-
ing differentiation, and closing of the mitochondrial permeability
transition pore (mPTP), as part of mitochondrial maturation, has
been shown to be required during cardiomyocyte differentiation.
Homet al. found that functionally and structurally immaturemito-
chondria, characteristic of early embryonic cardiomyocytes, dis-Cell Metabolism 18, Splayed open mPTP and consequently un-
coupled mitochondrial respiratory chain
(Hom et al., 2011). While closing of themPTP occurred during normal cardiomyocyte matura-
tion, chemical and genetic closing of the mPTP led to mitochon-
drial maturation and increased cardiomyocyte differentiation
(Hom et al., 2011). In conclusion, transition to an oxidative mito-
chondrial metabolism accompanied with the necessary func-
tional and structural maturation of mitochondria is key for the dif-
ferentiation of PSCs into specialized cell types.
The importance of mitochondria in cell differentiation has also
been demonstrated in developmental studies. Gene knockout of
essential factors (TFAM, POLG, POLG2, and NRF1) or cofactors
(PPRC1) for mitochondria biogenesis did not affect embryo im-
plantation but caused embryonic lethality at a later stage due
to mtDNA depletion, as well as insufficient supply of energy
and metabolites required for cell differentiation (Hance et al.,
2005; Humble et al., 2013; Huo and Scarpulla, 2001; Larsson
et al., 1998). Interestingly, a homozygous mutation (D257A) of
POLG in mice resulted in decreased DNA proofreading capacity
without apparently affecting polymerase activity, which subse-
quently caused an accumulation of mtDNAmutations (Trifunovic
et al., 2004). It is also reported that mitochondrial POLG mutant
mice did not exhibit severe phenotype at fetal stage, but showed
premature aging syndrome at adult stage presumably caused by
defects of adult stem cell populations (Ahlqvist et al., 2012).
Therefore, these models may provide ideal opportunities to
study the effects of mitochondrial dysfunction caused by the
accumulation of mtDNA mutations during aging on stem cells.
Mitochondria and Reprogramming
The reprogramming of somatic cells into a pluripotent state by
the expression of four transcription factors was successfully
established by Takahashi et al. in 2006 (Takahashi and Yama-
naka, 2006; Yu et al., 2007). Thereafter, the role of mitochondria
in the process of reprogramming has attracted tremendous
interest in the stem cell field. Previous studies haveeptember 3, 2013 ª2013 Elsevier Inc. 327
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to structural and functional remodeling of parental mitochondria
in both mouse and human somatic cells to a state resembling
PSCs. These changes include the transition from somatic oxida-
tive phosphorylation to glycolysis achieved through trans-
criptional and epigenetic regulation of gene expression, the
consequent upregulation of glycolytic genes and downregula-
tion of mitochondrial respiratory chain complexes, and reduction
in mtDNA copy number and changes in the structure and
morphology of mitochondria to a functionally immature state
(Folmes et al., 2011; Prigione et al., 2010; Suhr et al., 2010;
Varum et al., 2011). As expected, several studies have shown
that a switch from OXPHOS to glycolysis is necessary to repro-
gram somatic cells to pluripotency (Folmes et al., 2011; Pano-
poulos et al., 2012; Prigione et al., 2010; Varum et al., 2011),
and the key molecular pathways involved in this metabolic tran-
sition have been discussed (Zhang et al., 2012a). By comparing
metabolic and protein profiles in mouse iPSCs with their somatic
counterparts, Folmes et al. demonstrated increased expressions
of glycolytic enzymes and decreased mitochondrial activities
in iPSCs. Interestingly, when monitoring the time course of re-
programming, researchers found that metabolic transition from
OXPHOS to glycolysis was prior to the induction of pluripotency.
In cells with higher mitochondrial membrane potential, expres-
sions of glycolytic genes (Glut1, Hxk2, Pfkm, and Ldha) were
significantly increased within the first week of reprogramming,
whereas expressions of pluripotent genes (Fgf4, Nanog, Oct4,
and Sox2) remained at low levels (Folmes et al., 2011, 2012; Pan-
opoulos and Izpisua Belmonte, 2011). Panopoulos et al. also
reported changes in the epigenetic status of genes involved in
glycolysis and mitochondrial OXPHOS pathway during reprog-
ramming (Panopoulos et al., 2012). In addition, comparing
global metabolite profiles of human iPSCs, ESCs, and fibro-
blasts, researchers found that although iPSCs and ESCs have
similar glycolytic metabolism, differences at the levels of unsat-
urated fatty acids and S-adenosyl methionine may play impor-
tant roles during reprogramming (Panopoulos et al., 2012). As
expected, somatic cells with higher glycolytic metabolism dis-
played higher reprogramming efficiency than their highly oxida-
tive counterparts (Panopoulos et al., 2012). In this line, Zhu
et al. demonstrated that induced pluripotency could be achieved
with a combination of only one transcription factor (OCT4) and a
cocktail of small molecules including PS48, a potent activator of
PDK1 (pyruvate dehydrogenase kinase 1) that facilitates the
metabolic transition from mitochondrial oxidation to glycolysis.
Consequently, reprogramming efficiency was stimulated when
glycolysis was induced and inhibited when glycolysis was
blocked by small compounds (Zhu et al., 2010). This study not
only highlights the importance of mitochondrial function and
metabolism during reprogramming but also demonstrates that
the metabolic transition can induce cellular changes capable of
driving cells to a pluripotent state. Varum et al. found that
PSCs exhibited elevated levels of phosphorylated PDH that
blocked PDH complex activity and resulted in fewer substrates
entering the TCA cycle. Authors also demonstrated that the
levels of Hexokinase II were higher in PSCs than in fibroblasts
(Varum et al., 2011). More recently, Vazquez-Martin and col-
leagues revealed that the expression of ATPase inhibitor factor 1
(IF1) was significantly increased in iPSCs whereas the level328 Cell Metabolism 18, September 3, 2013 ª2013 Elsevier Inc.of catalytic b-F1-ATPase subunit was drastically decreased.
When activities of the acetyl-CoA carboxylase (ACACA) and fatty
acid synthase (FASN) lipogenic enzymes are inhibited, reprog-
ramming efficiency is significantly decreased. Coincidentally,
ACACA and FASN are highly expressed in iPSCs (Vazquez-
Martin et al., 2013). Interestingly, mitochondrial parameters
observed in cancer stem cells (CSCs) including mitochondrial
mass, mitochondrial morphology, mtDNA copy number, and
oxygen consumption are similar to those observed in iPSCs,
which may imply some common metabolic features between
iPSCs and CSCs that may help in their further characterization
and study (Varum et al., 2011; Ye et al., 2011).
Regarding mitochondrial dynamics, mitochondrial fission and
fusion events that regulate mitochondrial distribution have been
suggested to play important roles in the reprogramming process
as well. When fission is blocked using a Drp-1 inhibitor, somatic
cells fail to form net-like mitochondria, which consequently leads
to a decrease in reprogramming efficiency of more than 95%.
While the precise mechanism is still elusive, disturbance of the
metabolic transition is suggested to be involved in this correla-
tion (Vazquez-Martin et al., 2012). These data indicate that not
only functional but also structural changes in mitochondria
represent a requirement for successful nuclear reprogramming.
Finally, Prigione et al. showed that induced pluripotency by
nuclear reprogramming in iPSCs can introduce homoplasmic
and heteroplasmic mtDNA mutations; however, probably due
to the highly PSC-like glycolytic metabolism of iPSCs, these
mutations do not affect metabolic reprogramming and induced
pluripotency (Prigione et al., 2011).
Mitochondrial Disease Modeling and Gene Correction
The reprogramming of patient fibroblasts with mitochondrial
defects provides a great model for pathological studies, drug
screening, and cell-replacement therapy development. Since
mitochondria are semiautonomous organelles and contain their
own mitochondrial genetic material, mitochondrial disorders
can be the results of mitochondrial dysfunction caused by
mutations in the nuclear DNA (coding for multiple mitochondrial
proteins) or mtDNA (coding for 13 proteins, 22 tRNAs, and 2
rRNAs). iPSCs from patients with mutations in the nuclear
DNA have been widely established. For example, Cooper
et al. (2012) generated iPSCs from Parkinson’s disease (PD)
patients carrying mutations in PINK1, a mitochondrial protein
encoded by nuclear DNA, as well as LRRK2, a cytoplasmic
protein that can interact with the mitochondrial outer mem-
brane. Researchers found that neural cells differentiated from
patient-specific iPSCs could be phenotypically rescued by
certain chemicals. PD patient-specific iPSC-derived neural cells
carrying PINK1 Q456X or LRRK2 mutations can be rescued by
the antioxidant coenzyme Q10 or the LRRK2 inhibitor GW5074
in response to low concentrations of specific mitochondrial
damage inducers such as valinomycin and concanamycin A.
Additionally, rapamycin could reduce the vulnerability of neural
cells derived from PD patient iPSCs with the LRRK2 G2019S or
R1441C mutation to mitochondrial damage exposed to valino-
mycin. Another study by Jiang et al. demonstrated that in hu-
man midbrain dopaminergic (DA) neurons derived from iPSCs
of patients with Parkin mutations (a mitochondria-related ubiq-
uitin E3 ligase encoded by nuclear DNA), the levels of ROS,
Figure 2. Mitochondrial Disease-Modeling
and Gene Correction
(A) Reprogramming of fibroblasts from mitochon-
drial disease patients with mitochondrial dysfunc-
tion caused by mutations in mitochondrial DNA
(Mt mutant). Mutant mtDNA may exist as a mixture
of wild-type and mutant mtDNA (heteroplasmy).
MtDNA mutant (Mt mutant) iPSCs derived from
patients will give rise to two iPSC populations:
Mt-mutation-rich iPSCs with high levels of mutant
mtDNA and Mt-mutation-free-iPSCs with unde-
tectable levels of mutant mtDNA. Mt-mutation-rich
iPSCs represent valuable models for studying
mitochondrial diseases, whereas the Mt-mutation-
free iPSCs would be a promising resource for the
potential autologous cell therapy. Alternatively, Mt
mutations could be potentially corrected through
gene targeting.Mtmutantmitochondriaarecolored
in red; normal mitochondria are colored in green.
(B) Reprogramming of fibroblast from mito-
chondrial disease patients with mitochondrial
dysfunction caused by mutations in the nuclear
genome (Nc mutant). Nc-mutation-bearing iPSCs
may be used as a model of mitochondrial dis-
eases, whereas Nc-mutation-corrected iPSCs
(Nc-mutation-free iPSCs) will be a promising
resource for the autologous cell therapy. Defec-
tive mitochondria are colored in red; nor-
mal mitochondria are colored in green.
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Meanwhile, DA uptake was remarkably reduced with increased
spontaneous DA release (Jiang et al., 2012). Finally, Hick et al.
(2013) generated iPSCs from Friedreich’s ataxia (FRDA)
patients. Friedreich’s ataxia is a neurodegenerative disease
caused by expanded GAA codon repeats in the gene encoding
for frataxin, a mitochondrial protein involved in the biosynthesis
of iron-sulfur clusters. Neurons and cardiomyocytes derived
from iPSCs from FRDA patients display mitochondrial dysfunc-
tion and recapitulate the mitochondrial degeneration character-
istic of Friedreich’s ataxia, indicating that iPSCs from these
patients represent useful models for the study of this human dis-
order. These studies demonstrate that cells with mitochondrial
deficits can be reprogrammed into a pluripotent state and
that patient-specific iPSCs can be used as reliable models for
disease study and drug discovery.
On the other hand, distinct from nuclear DNA mutations,
mutations on mtDNA have also led to interesting observations
during reprogramming to induced pluripotency. To date, only a
few studies have been reported regarding iPSC reprogram-
ming from patients with mtDNA mutation. Fujikura et al. (2012)
reported the successful generation of mitochondrial disease-
specific iPSCs (Mt-iPSC) from two diabetic patients carrying
the mtDNA A3243G heteroplasmic mutation. Strikingly, they
found that some of the Mt-iPSC clones became mutation-free
during reprogramming while the others became mutation-rich.
The authors also found that while the mtDNA copy number in
Mt-iPSCs was similar to that of primitive fibroblasts at early
stage, it became similar to that of human ESCs at later stage.
Similar results were also found in another study where iPSCs
were generated from fibroblasts of a Pearson marrow pancreas
syndrome (PS) patient carrying heteroplasmic deletion in
mtDNA. Compared to mtDNA deletion-free iPSCs, PS-iPSCs
carrying deleted mtDNA displayed growth defects, mitochon-
drial dysfunction, and other disease-related phenotypes duringin vitro hematopoietic differentiation (Cherry et al., 2013). More
recently, Folmes et al. (2013) found that reprogramming fibro-
blasts derived from aMELAS patient (with a heteroplasmic mito-
chondrial mutation at position G13513A in the ND5 subunit
of complex I) produced iPSCs with a spectrum of healthy and
disease-causing mitochondrial heteroplasmy. Based on this
observation, the authors proposed that disease-causing mito-
chondrial heteroplasmy could be segregated in patient-derived
iPSCs. Therefore, iPSC-based mitochondrial disease models
may provide fascinating tools to investigate molecular features
of cellular dysfunction within the context of a native nuclear
genome background where distinct levels of mitochondrial het-
eroplasmy could be segregated. Nevertheless, it is still unclear
if heteroplasmy of mtDNA mutations in individual iPSC clones
is inherited from the heteroplasmy of parental fibroblasts or
generated de novo during the reprogramming process. Never-
theless, mutation-free iPSCs generated from patients may pro-
vide new promises for the autologous cell transplantation based
therapy, as illustrated in Figure 2.
Mitochondrial dysfunction is involved in many neurological
diseases (Rugarli and Langer, 2012) and aging (George et al.,
2011). In this regard, recent studies have thrown new light
on the understanding of these diseases using iPSC disease
modeling and gene targeting technology (Liu et al., 2011, 2012;
Pan et al., 2011; Zhang et al., 2012b). The advancing technology
of gene targeting in PSCs offers a novel approach to investigate
mitochondrial function as well asmitochondria-related diseases.
Despite the success achieved in nuclear gene editing, for many
decades targeting mitochondrial genomes harboring pathologic
mutations by gene editing tools has been a difficult task. En-
couragingly, a recent report by Iyer et al. (2012) described a
novel mitochondrial gene replacement technology to target
mtDNA. In this study, authors introduced a Leber’s hereditary
optic neuropathy (LHON) pathogenic mtDNA containing a
G11778A mutation. This pathogenic mtDNA was transfectedCell Metabolism 18, September 3, 2013 ª2013 Elsevier Inc. 329
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itor cells with reduced endogenous mtDNA. This LHON-hNP line
contained LHON mtDNA and had the capacity to differentiate
into neurons. Interestingly, Wang et al. (2012) reported success-
ful mitochondrial targeting of nuclear-encoded mRNAs and
tRNAS when they were appended to a 20-ribonucleotide stem-
loop sequence from the H1 RNA or a 30 UTR localization
sequence that confers localization to the mitochondrial outer
membrane. Consequently, RNA fusion transcripts were directed
into mitochondria. This study demonstrated that translocation of
a wide range of RNAs with or without mitochondrial localization
sequence can be achieved by appending amitochondrial target-
ing sequence and potentially provides an exciting tool for cor-
recting mitochondrial genetic disorders. Despite many years of
unsuccessful attempts for the manipulation of mtDNA, these
novel mtDNA editing-based approaches have opened the door
for the creation of novel in vitro stem cell models and the discov-
ery of therapies for mitochondrial disorders and neurodegenera-
tive diseases. Nevertheless, validation of successful and stable
mtDNA manipulation as well as application of these strategies
tomultiplemtDNA geneswill need to be validated before the field
can move forward.
Future Prospects
Mitochondria play vital roles in the induction and maintenance of
pluripotency, as well as in the differentiation of PSCs. While
recent advances have started to provide insights into these pro-
cesses, we are far from a comprehensive understanding of mito-
chondria physiological functions in stem cells. Questions that
need to be addressed include: (1) What is the role of mitochon-
dria in regulating reprogramming and differentiation? (2) Are
the functional and structural changes of mitochondria observed
in the pluripotent state and during differentiation the cause or
consequence of these processes? (3) What is the driving mech-
anism for the conversion of functionally maturemitochondria into
an immature state and vice versa during reprogramming and dif-
ferentiation, respectively? (4)What signaling pathways are deter-
mining these changes? (5) How is the mitochondrial network
remodeled during reprogramming and differentiation? (6) What
are the epigenetic modifications associated with changes in
mitochondrial biogenesis, function, and structure? (7) Is mitoph-
agy a crucial cellular process during nuclear reprogramming and
induced pluripotency? Besides these open questions, due to the
specific anabolic and catabolic requirements of PSCs when
compared with their differentiated counterparts, it is evident
that there is a metabolic transition from mitochondrial oxidative
phosphorylation to glycolysis during the establishment of plurip-
otency. This metabolic switch is accompanied by significant
changes in mitochondrial function, composition, structure, and
maturation in order to meet the specific cellular demands of
this cellular state. Understanding in more detail the role of mito-
chondria during these events and the mechanism behind these
changes will not only provide important insights into the relation-
ship between mitochondria and pluripotency, but may also
contribute specifically to our understanding of induced pluripo-
tency, embryonic development, and disease pathogenesis.
Furthermore, the fascinating advances of gene targeting tech-
nology in the stem cell field will substantially accelerate mecha-
nistic studies of aging and mitochondrial diseases, which in turn330 Cell Metabolism 18, September 3, 2013 ª2013 Elsevier Inc.may facilitate the development of new treatments in the not too
distant future.
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